FDA accepts Biological License Application for reslizumab
Teva filled Biologics License Application for reslizumab Archives • NCK Pharma
Clinical Study Protocol Distribution of Eosinophils in Asthma after Reslizumab (DEAR). A 7-week, Placebo- Controlled, Double-Bli
Israeli Pharma gets FDA Approval for Asthma Antibody
Cinqair (reslizumab)- Asthma- by Saro Arakelians, PharmD- Episode # 123 - YouTube
How patients use CINQAIR® (reslizumab) Injection Cost Support Program Card
Teva's Severe Asthma Therapy Reslizumab Now Approved in Europe | RT
Cinqair (reslizumab) Injection for treatment of Severe Asthma and an Eosinophilic Phenotype - Clinical Trials Arena
Teva's Asthma Therapy Reslizumab Fails in Late-Stage Studies
Reslizumab in the treatment of inadequately controlled asthma in adults and adolescents with elevated blood eosinophils: clinical trial evidence and future prospects - Jorge Máspero, 2017
Advisory Committee Briefing Materials: Available for Public Release
Israeli Pharma gets FDA Approval for New Antibody against Severe Asthma | Free directory of clinics in Israel
Rx Item-Cinqair (Reslizumab) 10Mg/Ml Inj Sinle Use Vial 10Ml By Teva Respiratory
Teva Reports Two Successful Phase III Studies For Reslizumab In Asthma
Australian Public Assessment Report Reslizumab
Medication Detail
Older Patients with Asthma Do Well with Reslizumab | RT
Teva-Handok wins approval for anti-asthma injection < Pharma < Article - KBR
EU grants marketing authorisation for Teva's asthma drug Cinqaero - Pharmafile
Teva files MAA for asthma treatment reslizumab
Reslizumab Overview - Creative Biolabs
